厄达替尼是什么药？治疗什么病？

What kind of medicine is erdafitinib? What disease is treated? is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (1) susceptible to FGFR3 or FGFR2 genetic alterations. (2) During or after at least one prior line of platinum-containing chemotherapy, including receipt of neoadjuvant platinum-containing platinum-based chemotherapy within 12 days.

As early as 2005, the American pharmaceutical company Astex had collaborated with the UK Cancer Research Drug Discovery Group and Cancer Research Technologies Ltd. at the University of Newcastle (Newcastle) in the UK to start a research plan for FGFR inhibitors. In March 2018, the U.S. Food and Drug Administration (FDA) granted erdafitinib Breakthrough Therapy designation for the treatment of urothelial cancer.

On April 12, 2019, the FDA announced accelerated approval of erdafitinib. The tablet, marketed as Balversa®, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer whose disease has progressed despite platinum-based chemotherapy. It is the first FDA-approved targeted therapy for metastatic urothelial cancer.

Recommended dose: The starting dose is 8 mg once daily, taken orally on an empty stomach or with food. For patients whose serum phosphorus levels fall below the target value of 5.5 mg/dL between days 14 and 21, the dose is increased to 9 mg once daily until disease progression or intolerance. If vomiting occurs after taking the medicine, do not take it again. The next time you take the medicine, you should still follow the original interval. If you miss a dose, you can take it again according to the amount within the same day, and the next time you take the medicine, you should still follow the original interval.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: